Palvella Therapeutics (PVLA) Research & Development (2014 - 2026)
Palvella Therapeutics (PVLA) posted quarterly Research & Development of $9.3 million for Q1 2026, up 129.11% year-over-year from $4.1 million in Q1 2025, and up 31.08% quarter-over-quarter from $7.1 million in Q4 2025.
Palvella Therapeutics (PVLA) Research & Development (2014 - 2026) Analysis & Trends
Palvella Therapeutics (PVLA) has reported Research & Development for 13 consecutive years, with $9.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 129.11% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $28.1 million (up 149.99% YoY), while the FY2025 annual figure was $22.8 million, up 180.22% from the prior year.
- Research & Development advanced to $9.3 million in Q1 2026 per PVLA's latest filing, from $7.1 million in the prior quarter.
- Across five years, Research & Development topped out at $14.3 million in Q2 2023 and bottomed at -$28.6 million in Q4 2023.
- Historically, Research & Development has averaged $6.0 million across 5 years, with a median of $7.1 million in 2025.
- Annual changes were most pronounced in 2023 — Research & Development tumbled 313.41% — and 2025, when it jumped 314.02%.
- Palvella Therapeutics' Research & Development stood at $13.4 million in 2022, then sank by 313.41% to -$28.6 million in 2023, then jumped by 108.91% to $2.5 million in 2024, then soared by 180.02% to $7.1 million in 2025, then jumped by 31.08% to $9.3 million in 2026.
- Business Quant data shows PVLA's Research & Development at $9.3 million in Q1 2026, $7.1 million in Q4 2025, and $6.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Palvella Therapeutics | 2.25 Bn | 1.93 Bn | - | 12.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.47 Mn |
| Mar 31, 2026 | 9.33 Mn |
| Dec 31, 2025 | 7.12 Mn |
| Sep 30, 2025 | 6.53 Mn |
| Jun 30, 2025 | 5.12 Mn |
| Mar 31, 2025 | 4.07 Mn |
| Dec 31, 2024 | 2.54 Mn |
| Sep 30, 2024 | 3.18 Mn |
| Jun 30, 2024 | 1.44 Mn |
| Mar 31, 2024 | 984,000.00 |
| Dec 31, 2023 | -28.55 Mn |
| Sep 30, 2023 | 9.60 Mn |
| Jun 30, 2023 | 14.33 Mn |
| Mar 31, 2023 | 13.42 Mn |
| Dec 31, 2022 | 13.38 Mn |
| Sep 30, 2022 | 13.59 Mn |
| Jun 30, 2022 | 11.95 Mn |
| Mar 31, 2022 | 14.07 Mn |
| Dec 31, 2021 | 15.36 Mn |
| Sep 30, 2021 | 18.94 Mn |